Lilly Oncology Taking 'Aggressive' Position

Posted: Updated:
(Image of Sue Mahony courtesy of Eli Lilly and Co.) (Image of Sue Mahony courtesy of Eli Lilly and Co.)
INDIANAPOLIS -

The president of Lilly Oncology says the company has a "strong base" of existing and potential treatments to fuel a new strategy for its cancer-fighting pipeline. During an earnings call with investors Tuesday morning, Sue Mahony said the company's oncology unit will be more aggressive, particularly when it comes to potential treatments in earlier stages "that clear a high bar." Officials say Lilly Oncology will sharpen its focus on 10 internal assets, seven of which are currently in the pipeline.

Additionally, Mahony says, Lilly Oncology could continue to connect with other drug makers on partnerships to help drive treatments to market like one signed with Merck & Co. Inc. (NYSE: MRK) earlier this year. The goal, she says, is to boost business development. "Specifically, we will actively pursue assets that combine rationally with our existing products, serve as new potential foundational agents and enable new immuno-oncology breakthroughs," Mahony said. "The good news is that there is a lot of external innovation in oncology, and we intend to be much more active in this space to ensure we have a competitive pipeline going forward."

During a retooling of its business units announced earlier this year, Mahony stayed on as a senior vice president and as president of Lilly Oncology.

Senior Vice President of Global Development and Medical Affairs Levi Garraway, who joined the company in January, says Lilly Oncology is positioned for a "remarkable" opportunity. He says "the vast majority of our internal R&D dollars" will now be focused on the aforementioned seven early-to-mid-stage assets in its oncology pipeline. One potential treatment, Abemaciclib, is awaiting regulatory approval, while several others are in the first, second or third phases of the development process. "We are giving ourselves flexibility to bet more aggressively on portfolio assets with the highest foundational potential," Garraway said, "while de-risking others externally, and importantly, making room to bring external innovation into our oncology portfolio."

During its second quarter earnings report Tuesday, Lilly detailed profit of more than $1 billion, a 35 percent increase from the same period a year earlier, and it revised previous full-year research and development investment expectations to a range of $5 billion to $5.2 billion.

Lilly Oncology President Sue Mahony says the company could continue to connect with other drug makers on partnerships to help drive treatments to market.
  • Perspectives

    • The Terrorist to Fear Most May be an Employee's Spouse

      As the world sees more small-scale terrorist attacks, some employers worry about their places of business becoming targets. The odds are much larger that they'll face a different kind of terror: one from an employee's personal life. The reality is that what we normally think of as terrorism presents only a miniscule threat to most Americans. There is, however, one very real threat of violence to your business.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Holcomb Nominates Opportunity Zones

      Governor Eric Holcomb has submitted nominations to the U.S. Secretary of the Treasury for dozens of Hoosier communities to earn the newly-created Opportunity Zone designation. The federal program, which was created with the passage of the Tax Cuts and Jobs Act, provides tax incentives to attract private investment to low-income communities.

    • The Terrorist to Fear Most May be an Employee's Spouse

      As the world sees more small-scale terrorist attacks, some employers worry about their places of business becoming targets. The odds are much larger that they'll face a different kind of terror: one from an employee's personal life. The reality is that what we normally think of as terrorism presents only a miniscule threat to most Americans. There is, however, one very real threat of violence to your business.

    • (Rendering provided by the city of Fishers.)

      Flexware Innovation Details New Fishers HQ

      Fishers-based Flexware Innovation Inc. is planning to relocate within the city to a new headquarters in a more prominent location. The company, which also has an office in Valparaiso and a presence at the new Indiana IoT Lab in Fishers, says the $3.5 million project near the Nickel Plate District Amphitheater could break ground in the fall. The company is seeking more than $265,000 in tax incentives from the city. Late last year, it announced plans to invest some $8 million into...

    • Six Finalists Vying For 'Stellar' Designation

      Six regions have been selected as finalists for the 2018 Stellar Communities Program. The initiative, which is taking a regional approach this year for the first time, involves support from the state to help boost strategic planning efforts in participating communities. Stellar Communities is driven by the Indiana Office of Community and Rural Affairs and previously involved smaller cities and towns. OCRA Executive Director Jodi Golden says...

    • Levementum Scores Funding, Sells Off Product

      Arizona-based Levementum, which has a growing presence in Indianapolis, says it has raised an additional $4 million in funding, led by Inoca Capital Partners. Chief Executive Officer Doug Guilbeau also says the company has sold its SugarCRM practice to focus on its Salesforce products and becoming "the top digital consultancy focused on consumer engagement." Levementum says the funding from the private equity firm will help support...